Northland Securities analyst Suraj Kalia maintained a Hold rating on Intersect ENT (NASDAQ: XENT) today and set a price target of $28. The company’s shares opened today at $29.57.
Kalia said:
“We had specifically referenced this drug and these Phase-III studies as risks on the horizon for SINUVA in our note dated 10/03/18. The Phase – III data raise many questions in our mind about SINUVA outlook and the competitive landscape. Caution is warranted vis-a-vis SINUVA. Key Points The f/u for the 2-trials was 24-wks, Dupilumab + mometasone furoate (Nasonex) spray 51% reduction in nasal congestion / obstruction severity vs. 15% for the control arm of mometasone furoate spray in SINUS-24 trial. The numbers stood at 57% and 19% for SINUS-52 trial.”
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 14.1% and a 60.9% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Apollo Endosurgery Inc, and Edwards Lifesciences.
Currently, the analyst consensus on Intersect ENT is a Moderate Buy with an average price target of $34.67.
See today’s analyst top recommended stocks >>
Based on Intersect ENT’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $4.16 million. In comparison, last year the company had a GAAP net loss of $4.26 million.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XENT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intersect ENT, Inc. is acommercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.
